A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus

OBJECTIVE: To compare skin-related outcomes in women with vulvar lichen sclerosus treated with fractionated carbon dioxide laser with concomitant clobetasol propionate 0.05% with women treated with fractionated carbon dioxide laser plus placebo ointment. METHODS: This randomized, double-blind, placebo-controlled multicenter trial was conducted at nine U.S. sites from March 2022 to April 2025. English- or Spanish-speaking adult women with lichen sclerosus electing vulvar fractionated carbon dioxide laser treatment were eligible. Women were excluded if they had prior vaginal mesh prolapse repair, previous radiation therapy, prior laser, immunomodulators or systemic therapy for lichen sclerosus, active genital infection, suspicious vulvar lesion or malignancy, active treatment for malignancy, or poor wound healing or if they were currently pregnant, lactating, or planning pregnancy. All participants underwent three vulvar fractionated carbon dioxide laser treatments 4-6 weeks apart and were randomized 1:1 to concomitant clobetasol propionate 0.05% or petrolatum-based ointment (placebo) 0.25-0.5 g nightly for 4 weeks starting at first laser treatment and then twice weekly until end of study. The primary outcome was proportion of women with improvement of 16 or more points on the Skindex-29, a validated questionnaire measuring a patient's skin-related symptoms and functioning, assessed at 4-5 weeks after completion of fractionated carbon dioxide laser treatment. Additional outcomes included Skindex-29 domain scores, patient impression of improvement (PGI-I [Patient Global Impression of Improvement] score), treatment satisfaction, and adverse events. RESULTS: Two hundred one participants were randomized, and 180 (89 clobetasol vs 91 placebo) had complete data. Most women indicated symptom onset 1 year or more before lichen sclerosus diagnosis, and approximately 90% had previously used topical corticosteroids. Nearly a third of all participants achieved the primary outcome (30.3% clobetasol vs 27.5% placebo, P=.67). Participants in the clobetasol arm demonstrated a greater improvement in Skindex-29 symptom score (mean change -19.0±18.5 clobetasol vs -10.1±19.8 placebo, P<.01) and total score (mean change -13.0±15.9 clobetasol vs -8.1±15.5 placebo, P=.04). More participants were "satisfied" or "very satisfied" with treatment after clobetasol (85.4% clobetasol vs 69.2% placebo, P=.01). Fifteen adverse events occurred in 12 participants (6 per cohort). CONCLUSION: There was no difference in the proportion of patients improving at least 16 points on the Skindex-29 after combined vulvar fractionated carbon dioxide laser and clobetasol compared with placebo. The clobetasol group reported greater improvement in lichen sclerosus-specific symptoms and higher treatment satisfaction. The rates of adverse events were low regardless of concomitant therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04951206.

Authors

Institutions

Publication Details

Journal
Obstetrics and Gynecology
Published
2026-11-17
DOI
https://doi.org/10.1097/aog.0000000000006476
Primary Topic
Genital Health and Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus

Kate V. Meriwether, Kimberly Kenton, Christine M. Vaccaro, Alexis Anne Dieter et al.
2 links
Obstetrics and Gynecology
Genital Health and Disease
article

A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus

Kate V. Meriwether, Kimberly Kenton, Christine M. Vaccaro, Alexis Anne Dieter, Ladin A. Yurteri-Kaplan, Cheryl Bernadette Iglesia, Lisa C. Hickman, Kimberly L. Ferrante, Mihriye Méte, Emily Von Bargen, Silpa Nekkanti, Holly E Richter, Cara Grimes, Meagan Simpson, Sarit Aschkenazi, Margaret G. Mueller, Melissa G. Goodwin, Akira Gillingham
article en

Abstract

OBJECTIVE: To compare skin-related outcomes in women with vulvar lichen sclerosus treated with fractionated carbon dioxide laser with concomitant clobetasol propionate 0.05% with women treated with fractionated carbon dioxide laser plus placebo ointment. METHODS: This randomized, double-blind, placebo-controlled multicenter trial was conducted at nine U.S. sites from March 2022 to April 2025. English- or Spanish-speaking adult women with lichen sclerosus electing vulvar fractionated carbon dioxide laser treatment were eligible. Women were excluded if they had prior vaginal mesh prolapse repair, previous radiation therapy, prior laser, immunomodulators or systemic therapy for lichen sclerosus, active genital infection, suspicious vulvar lesion or malignancy, active treatment for malignancy, or poor wound healing or if they were currently pregnant, lactating, or planning pregnancy. All participants underwent three vulvar fractionated carbon dioxide laser treatments 4-6 weeks apart and were randomized 1:1 to concomitant clobetasol propionate 0.05% or petrolatum-based ointment (placebo) 0.25-0.5 g nightly for 4 weeks starting at first laser treatment and then twice weekly until end of study. The primary outcome was proportion of women with improvement of 16 or more points on the Skindex-29, a validated questionnaire measuring a patient's skin-related symptoms and functioning, assessed at 4-5 weeks after completion of fractionated carbon dioxide laser treatment. Additional outcomes included Skindex-29 domain scores, patient impression of improvement (PGI-I [Patient Global Impression of Improvement] score), treatment satisfaction, and adverse events. RESULTS: Two hundred one participants were randomized, and 180 (89 clobetasol vs 91 placebo) had complete data. Most women indicated symptom onset 1 year or more before lichen sclerosus diagnosis, and approximately 90% had previously used topical corticosteroids. Nearly a third of all participants achieved the primary outcome (30.3% clobetasol vs 27.5% placebo, P=.67). Participants in the clobetasol arm demonstrated a greater improvement in Skindex-29 symptom score (mean change -19.0±18.5 clobetasol vs -10.1±19.8 placebo, P<.01) and total score (mean change -13.0±15.9 clobetasol vs -8.1±15.5 placebo, P=.04). More participants were "satisfied" or "very satisfied" with treatment after clobetasol (85.4% clobetasol vs 69.2% placebo, P=.01). Fifteen adverse events occurred in 12 participants (6 per cohort). CONCLUSION: There was no difference in the proportion of patients improving at least 16 points on the Skindex-29 after combined vulvar fractionated carbon dioxide laser and clobetasol compared with placebo. The clobetasol group reported greater improvement in lichen sclerosus-specific symptoms and higher treatment satisfaction. The rates of adverse events were low regardless of concomitant therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04951206.

Obstetrics and Gynecology
Georgetown University (US), Institute for Female Pelvic Medicine and Reconstructive Surgery (US)
Good health and well-being
Genital Health and Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon